PMID- 25409926
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20161126
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1853
IP  - 1
DP  - 2015 Jan
TI  - Biphasic effects of luteolin on interleukin-1beta-induced cyclooxygenase-2 
      expression in glioblastoma cells.
PG  - 126-35
LID - S0167-4889(14)00369-3 [pii]
LID - 10.1016/j.bbamcr.2014.10.010 [doi]
AB  - Success in developing therapeutic approaches to target brain tumor-associated 
      inflammation in patients has been limited. Given that the inflammatory 
      microenvironment is a hallmark signature of solid tumor development, 
      anti-inflammatory targeting strategies have been envisioned as preventing 
      glioblastoma initiation or progression. Consumption of foods from plant origin is 
      associated with reduced risk of developing cancers, a chemopreventive effect that 
      is, in part, attributed to their high content of phytochemicals with potent 
      anti-inflammatory properties. We explored whether luteolin, a common flavonoid in 
      many types of plants, may inhibit interleukin (IL)-1beta function induction of the 
      inflammation biomarker cyclooxygenase (COX)-2. We found that IL-1beta triggered 
      COX-2 expression in U-87 glioblastoma cells and synergized with luteolin to 
      potentiate or inhibit that induction in a biphasic manner. Luteolin pretreatment 
      of cells inhibited IL-1beta-mediated phosphorylation of inhibitor of kappaB, nuclear 
      transcription factor-kappaB (NF-kappaB) p65, extracellular signal-regulated kinase-1/2, 
      and c-Jun amino-terminal kinase in a concentration-dependent manner. Luteolin 
      also inhibited AKT phosphorylation and survivin expression, while it triggered 
      both caspase-3 cleavage and expression of glucose-regulated protein 78. These 
      effects were all potentiated by IL-1beta, in part through increased nuclear 
      translocation of NF-kappaB p65. Finally, luteolin was able to reduce IL-1 receptor 
      gene expression, and treatment with IL-1 receptor antagonist or gene silencing of 
      IL-1 receptor prevented IL-1beta/luteolin-induced COX-2 expression. Our results 
      document a novel adaptive cellular response to luteolin, which triggers 
      anti-survival and anti-inflammatory mechanisms that contribute to the 
      chemopreventive properties of this diet-derived molecule.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Lamy, Sylvie
AU  - Lamy S
AD  - Laboratoire d'Oncologie Moleculaire, Centre de Recherche BioMed, Universite du 
      Quebec a Montreal, C.P. 8888, Succ. Centre-ville, Montreal, Quebec H3C 3P8, 
      Canada. Electronic address: lamy.sylvie@uqam.ca.
FAU - Moldovan, Paula Liana
AU  - Moldovan PL
AD  - Laboratoire d'Oncologie Moleculaire, Centre de Recherche BioMed, Universite du 
      Quebec a Montreal, C.P. 8888, Succ. Centre-ville, Montreal, Quebec H3C 3P8, 
      Canada. Electronic address: moldovan.paula_liana@courrier.uqam.ca.
FAU - Ben Saad, Aroua
AU  - Ben Saad A
AD  - Laboratoire d'Oncologie Moleculaire, Centre de Recherche BioMed, Universite du 
      Quebec a Montreal, C.P. 8888, Succ. Centre-ville, Montreal, Quebec H3C 3P8, 
      Canada. Electronic address: ben_saad.aroua@courrier.uqam.ca.
FAU - Annabi, Borhane
AU  - Annabi B
AD  - Laboratoire d'Oncologie Moleculaire, Centre de Recherche BioMed, Universite du 
      Quebec a Montreal, C.P. 8888, Succ. Centre-ville, Montreal, Quebec H3C 3P8, 
      Canada. Electronic address: annabi.borhane@uqam.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141018
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (Interleukin-1beta)
RN  - 0 (Receptors, Interleukin-1)
RN  - 0 (Transcription Factor RelA)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - KUX1ZNC9J2 (Luteolin)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Cyclooxygenase 2/*genetics
MH  - Gene Expression Regulation, Enzymologic/drug effects
MH  - Glioblastoma/*enzymology
MH  - Humans
MH  - Interleukin-1beta/*pharmacology
MH  - Luteolin/*pharmacology
MH  - MAP Kinase Signaling System/physiology
MH  - Receptors, Interleukin-1/physiology
MH  - Transcription Factor RelA/metabolism
OTO - NOTNLM
OT  - COX-2
OT  - Glioblastoma
OT  - Inflammation
OT  - Interleukin-1
OT  - Luteolin
OT  - NF-kappaB
EDAT- 2014/11/21 06:00
MHDA- 2015/01/30 06:00
CRDT- 2014/11/21 06:00
PHST- 2014/05/28 00:00 [received]
PHST- 2014/10/10 00:00 [revised]
PHST- 2014/10/13 00:00 [accepted]
PHST- 2014/11/21 06:00 [entrez]
PHST- 2014/11/21 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
AID - S0167-4889(14)00369-3 [pii]
AID - 10.1016/j.bbamcr.2014.10.010 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2015 Jan;1853(1):126-35. doi: 10.1016/j.bbamcr.2014.10.010. 
      Epub 2014 Oct 18.